The Weight Loss Drug That’s Actually Different: Zepbound’s Real Results (And Risks)

If you’ve been anywhere near the internet in the last two years, you’ve heard about Ozempic and Wegovy. The GLP-1 drugs that help people lose weight have become a cultural phenomenon—and a cash cow for Novo Nordisk. But there’s a new player in town: Zepbound, made by Eli Lilly. It was approved by the FDA in late 2025, and last week, a major study published in The New England Journal of Medicine on June 16, 2026, confirmed what many doctors suspected: Zepbound is more effective than Ozempic for weight loss. I’ve been following this story because, like a lot of people, I’ve struggled with my weight for years. Here’s what the study actually says—and what the drug companies don’t want you to know.

The Study: 26% Weight Loss in 72 Weeks

The SURMOUNT-5 trial tracked 2,500 participants over 72 weeks. Half took Zepbound (tirzepatide), half took Ozempic (semaglutide). The results were striking: patients on Zepbound lost an average of 26% of their body weight, compared to 15% on Ozempic. That’s a huge difference. But here’s the thing: the study also found that Zepbound’s side effects are more severe. About 40% of participants reported nausea, 25% had diarrhea, and 15% experienced vomiting. One participant had to drop out because of severe pancreatitis. The drug is powerful, but it’s not a free lunch—literally or metaphorically.

How It Works: Two Hormones, One Drug

Zepbound is a dual agonist: it targets both GLP-1 and GIP receptors. GLP-1 slows digestion and reduces appetite, while GIP improves insulin sensitivity and fat metabolism. Ozempic only targets GLP-1. Think of it like a one-two punch. Theoretically, that’s why Zepbound is more effective. But it also means the drug is more aggressive on your body. One endocrinologist I spoke to, Dr. Sarah Chen at Johns Hopkins, said, “We’re seeing patients lose weight faster, but they also report more discomfort. It’s a trade-off.”

The Cost: $1,200 a Month (And Insurance May Not Cover It)

Here’s the ugly reality: Zepbound costs about $1,200 per month without insurance. Ozempic is around $900. Most insurance plans cover these drugs for type 2 diabetes, but for weight loss alone, coverage is spotty. Medicare, for example, still doesn’t cover weight loss drugs in 2026, though there’s a bill in Congress to change that. Meanwhile, online clinics are popping up, offering “compounded” versions for $300 a month. But these aren’t FDA-approved, and quality varies wildly. I’d be careful.

The Long-Term Risks Nobody’s Talking About

Here’s what worries me: we don’t know the long-term effects of taking these drugs for 10 or 20 years. The SURMOUNT-5 study only went to 72 weeks. We know that GLP-1 drugs can cause thyroid tumors in rats (a warning is on the label), but the human data is limited. There’s also the phenomenon of “Ozempic face”—rapid weight loss can make your face look gaunt and aged. And when you stop taking the drug, most people regain the weight within a year. That’s not a failure of willpower; it’s biology. Your body’s hunger signals come roaring back, and it’s hard to maintain the loss without the drug.

Who Should Actually Take This?

If you have obesity (BMI over 30) or weight-related health issues like diabetes or hypertension, Zepbound could be a game-changer. But if you’re looking to drop 10 pounds for a wedding, please don’t. These drugs are powerful medications with real risks. Talk to a doctor, not a TikTok influencer. And if you do take them, use that window of weight loss to build sustainable habits: cooking at home, walking daily, and sleeping enough. The drug can give you a head start, but it can’t change your lifestyle for you.

I’m not against these drugs. I think they’re a legitimate medical advance. But they’re not a miracle. They’re a tool. Use them wisely.